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Background: Βeta-2-microglobulin (β2-M) has been demonstrated as a growth factor and signaling molecule in
breast cancer and leukemia. The purpose of the study is to characterize β2-M expression in molecular subtypes of
breast cancer, thereby investigating the mechanism of β2-M action in breast cancer.
Methods: β2-M and B-Cell Lymphoma/Leukemia 2 (Bcl-2) transcript expression levels in breast cancer tissue and
the corresponding normal tissue were quantified using real-time PCR. The protein expression levels of β2-M,
estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor 2 (HER-2), tumor
protein 53 (p53) and Ki67 were determined by immunohistochemical (IHC) staining. Following silencing of the
β2-M by siRNA, the levels of Bcl-2, ER, PR and HER-2 transcripts and the protein expression levels in human
breast cancer cells were measured by real-time PCR and western blotting, respectively.
Results: The expression of β2-M transcripts demonstrated no significant differences between the four breast
cancer molecular subtypes and no significant correlations with age, clinical stage or lymph node metastasis.
β2-M transcript expression demonstrated a positive correlation when compared to Bcl-2 transcript expression
(P < 0.05). The β2-M protein expression was significantly higher in breast cancer when compared with benign
breast tumors (P < 0.01), and have no significant correlation with age, clinical stage or lymph node metastasis.
There was a significant difference demonstrated in β2-M protein expression in the four breast cancer molecular
subtypes (P < 0.05), and between the ER+ and ER− groups (P < 0.01); however, no significant difference was
demonstrated between the HER-2+ and HER-2− groups. β2-M protein expression had a negative correlation
with ER protein expression (P < 0.01), a positive correlation with p53 protein expression (P < 0.01), and no correlation
with Ki67 protein expression. β2-M silencing significantly inhibited Bcl-2 mRNA expression, but did not inhibit ER, PR
and HER-2 mRNA expression in MCF-7 cells (ER+, PR+ and HER-2−). In addition, Bcl-2 and HER-2 mRNA expression were
significantly up-regulated in MDA-MB-231 cells (ER−, PR− and HER-2−), which is consistent with the silencing effect seen
at the protein level.
Conclusions: β2-M expression demonstrated a significant difference in the four breast cancer molecular subtypes, and
may be related to apoptosis regulation in breast cancer.
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Case no. 164 166 330
Age (years)
<59 126 143 269
≥60 37 21 58
Stage
I + II 55 57 112
III + IV 29 40 69
Lymph node metastasis
Present 59 34 93
Absent 63 53 116
Benign breast tumors 123 0 123
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β2-M is a low molecular weight protein and is part of
the HLA antigen molecule, representing the invariant
light chain [1,2]. It exists in the membrane of almost all
nucleated cells, and is detectable in all body fluids as a
shedding product of the cell membrane [3]. In renal dis-
ease that presents with the damage of the tubuli renales
and increased glomerular filtration rates, quantities of
β2-M in urine are increased. If the rate of glomerular fil-
tration is reduced, the level of serum β2-M is increased
[4]. Therefore, serum and urine concentrations of β2-M
are used to monitor glomerular and tubular nephropa-
thies [5]. The levels of serum and urine β2-M are also
found to be increased in patients with some tumors, in-
cluding solid tumors and leukemia [6-9]. Thus, the levels
of serum β2-M have become one of the most important
prognostic factors and predictors of survival in patients
with some tumors [7-9]. Studies have reported that
β2-M is a growth factor and signaling molecule in cancer
cells [10-12] and is also a pleiotropic signaling molecule
that regulates p21-activated kinases (PAK), androgen re-
ceptor, vascular endothelial growth factor (VEGF), fatty
acid synthase [12], lipid-raft-mediated growth and survival
signaling pathways [13]. The role of β2-M has been dem-
onstrated in several solid cancers and leukemia; however,
the mechanism of β2-M action is poorly understood.
Although increased β2-M serum levels in patients with
breast cancer have been previously reported [6,9,12], the
clinical value of β2-M as a prognostic factor and pre-
dictor of survival, and its mechanism in patients with
breast cancer, need further study, since breast cancer has
different molecular subtypes [14] and patients with the
same clinical stages and pathological types of breast cancer,
treated with same scheme, have different therapeutic and
prognostic effects. The aim of this study is to characterize
β2-M expression in the different breast cancer molecular
subtypes, thereby investigating whether β2-M is involved
with apoptosis regulation in breast cancer. The results of
this study will be useful in confirming β2-M-mediated sig-
naling as a new target for breast cancer therapy.
Methods
Tissue samples
The tissue samples in this study were collected from 330
patients with breast cancer and 123 patients with benign
breast tumors, identified by clinical and histopathological
evidence, who underwent surgery at Tumor Hospital of
Gansu province. The 164 breast cancer and 123 benign
breast tumor tissue samples were from formalin-fixed,
paraffin-embedded (FFPE) tissue specimens obtained from
the pathology department during surgery performed be-
tween 2011 and 2012. The other 166 breast cancer and ad-
jacent normal fresh tissue samples were obtained from
surgical specimens resected from patients without previouschemotherapy and radiotherapy during operations per-
formed or examinations by centesis between 2010 and
2013. The fresh tissue samples were frozen at −80°C for
preparation of total RNA extraction. The clinicopathologi-
cal information, including age, node status and tumor-
node-metastasis (TNM), was obtained from each patient’s
clinical and pathologic reports. The patient character-
izations are listed in Table 1. The Medical Ethics Commit-
tee of Medicine and Science Research Institute of Gansu
Province approved the study protocol (Reference number:
A201301310001) and all patients gave consent for partici-
pating in the study and publishing the study results.
Total RNA extraction and real-time PCR
Total RNA was extracted from the tumor tissues and the
adjacent normal tissues using Trizol reagent (Shenggong
Biotechnology, Shanghai, China) according to the manufac-
turer’s instructions. The cDNA was synthesized by reverse
transcription using the RNA as a template and reverse
transcriptase (Shenggong Biotechnology), according to the
manufacturer’s recommendations. The SYBR premix Ex
TaqTM (TaKaRa Biotechnology, Dalian, China) was used
for the real-time PCR. Briefly, the 20 μl reaction contained
10 μl of SYBR premix Ex TaqTM, 1 μl of DNA template,
0.4 μl of each primer and 8.2 μl dH2O. The PCR cycling
conditions included the following steps: 37°C for 5 min,
95°C for 30 s, and 40 cycles of 95°C for 5 s to 60°C for
30 s. β-actin mRNA was used as the internal control and
the reaction mix without template DNA was used as the
negative control. All of the samples were measured 3
times independently, and the resulting fluorescence curves
represent the number of DNA copies expressed. The
primers are listed in Table 2.
IHC staining
Expression of β2-M, ER, PR, HER-2, p53 and Ki67 in
tumor tissues were detected by IHC staining. Sections
Table 2 Primers used in the real-time PCR
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embedded in paraffin were used for IHC staining by the
standard method. Briefly, the paraffin-embedded tissues
were cut to a 3-mm thickness, de-paraffinized with xylene
and rehydrated through graded ethanol washes. The sec-
tions were autoclaved in 10 mM citrate buffer (pH 6.0) at
120°C for 5 min for antigen retrieval, cooled to 26°C,
treated with 3% H2O2 for 5–10 min to block endogenous
peroxidase activity, and then washed with phosphate-
buffered saline (PBS, pH 7.3) for 3 min 3 times. After
being blocked with 10% normal calf serum in PBS for
10–15 min, the sections were incubated at 37°C for
2–3 h with anti-β2-M (developed by Department of
Medicine Biotechnology, Medicine and Science Institute
of Gansu Province, Lanzhou, China) at a 1:1000 dilution,
then washed with PBS. Next, the sections were incubated
with biotinylated secondary antibody (ZYMED, South San
Francisco, CA, USA) for 10–15 min at 37°C, and then
washed with PBS. Horseradish peroxidase polymer conju-
gate (SP-9000 Histostain TM-plus Kit, ZYMED) was then
applied to the sections at 37°C for 10–15 min followed by
PBS washes. Finally, the sections were incubated with 3-
3′-Diaminobenzidine (DBA) for 5–10 min. The nuclei
were lightly counterstained with hematoxylin. A negative
control was run simultaneously by omitting the primary
antibody. The stained slides were independently assessed
by two pathologists, and any differences in decision out-
comes were resolved by consensus. To evaluate the expres-
sion of β2-M, the tissue sections were examined under a
microscope at a magnification of 200×. The results of the
tissue sections staining were estimated according to the
following: positive, cytoplasm staining or both cytoplasm
and cytomembrane staining (mainly cytoplasm staining);
negative, no cytomembrane staining. The intensity of stain-
ing was classified according to the following scale: negative,
0; weak, 1; moderate, 2; and strong, 3. Staining was semi-
quantitatively scored according to proportion of stained
cells by the following scale: 0, no cells stained; 1, <10%; 2,
10-50%; and 3, >50% of cells stained. The staining intensity
scores and proportion of stained cells were added; the cut-
off value for positive expression of β2-M was defined as
moderate staining with >10% of cells stained.
The ER, PR, HER-2, p53 and Ki67 (Beijing Zhongshan
Jinqiao, Beijing, China) staining procedure was same asthat of β2-M described above. The results of tissue sections
stained for ER, PR, p53 and Ki67 were determined accord-
ing to the following: positive, nucleus staining or both nu-
cleus and cytoplasm staining (mainly nucleus staining);
negative, only cytoplasm staining. The cut-off value for
positive expression was the same as that of β2-M. The re-
sults of tissue sections stained for HER-2 were scored by
the ASCO/CAP system: positive, cytomembrane staining;
negative, no cytomembrane staining. The cut-off value for
positive expression of HER-2 was defined as having more
than 10% of the cells stained.
Silencing of the β2-M gene by siRNA in breast cancer cells
Three siRNAs targeting different regions of β2-M mRNA
[GenBank: NM014002] were designed and purchased
from GenePharma (Suzhou, China). Scrambled siRNA
(GenePharma) that does not target any gene was used
as the negative siRNA control. All siRNAs are detailed in
Table 3. Breast cancer cells (MCF-7 and MDA-MB-231,
purchased from the Shanghai Cell Bank of Chinese Acad-
emy of Sciences, Shanghai, China) were transfected with
the siRNAs using Lipofectamine-2000 according to the
manufacturer′s instructions. Briefly, cells were seeded in
a 6-well-plate at a density of 1 × 105 cells/well with
antibiotic-free medium 12 h before transfection. Two mi-
croliters of each siRNA (40 μM) were mixed with 3 μl
Lipofectamine-2000 in 50 μl serum-free RPMI-1640
medium and were allowed to incubate at room temperature
for 25 min to form a complex. After washing cells with
PBS, the 50 μl transfection mixtures were added to each
well with 1950 μl RPMI-1640 medium containing 10% FBS
at a final concentration of 40 nM siRNA. Forty-eight hours
after transfection, the cells were collected for real-time
RT-PCR and western blotting.
Western blotting
The cultured cells were washed twice with ice-cold PBS
and lysed on ice in lysis buffer containing protease and
phosphatase inhibitor cocktails. Following a 5-min incu-
bation, the cell lysate was collected by centrifugation at
4°C for 10 min at 12,000 rpm. Twenty micrograms of
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was transferred to a nitrocellulose membrane, blocked and
then probed with appropriate antibodies. The protein was
visualized using horseradish peroxidase-conjugated sec-
ondary antibodies and the FluorChem FC2 imaging sys-
tem. Anti-β2-M antibody (self-government), anti-β-actin
antibody (Rockland, Gilbertsville, PA, USA), anti-Bcl-2
antibody, anti-HER-2 antibody, anti-ER antibody, anti-PR
antibody and horseradish peroxidase-conjugated second-
ary antibody (Invitrogen, Carlsbad, CA, USA) were used
for western blotting.
Statistical analysis
The data were analyzed using the Statistical Package
for Sciences software (IBM-SPSS version 22). The statis-
tical significance of intergroup differences was evalu-
ated using a χ2 test. P < 0.05 was considered statistically
significant.
Results
Expression of β2-M transcripts in breast cancer tissues
The expression of β2-M transcripts was detected by real-






Case no. 26 106 34
Stage
I-II 11 35 11
III-IV 5 27 8
Age (years)
<40 3 15 4
40-60 21 74 26
>60 2 16 3
Lymph node metastasis
Present 3 22 9
Absent 10 34 9
Molecular subtype
Luminal A 4 33 12
Luminal B 8 30 11
Overexpression of HER-2 5 19 6
Basal-like 2 8 3
ER+ 12 63 23
ER− 8 29 10
HER-2+ 14 50 18
HER-2− 6 42 15paired normal tissues. The specimens were divided into
three groups according to the ratio of the β2-M transcript
levels in the tumor tissue (T) to that in the normal tissue
(N): up-regulation (T/N > 2), down-regulation (T/N < 0.5)
and no change in expression (2 > T/N > 0.5). The results
are shown in Table 4 and demonstrate the following:
15.66% (26/166) up-regulation, 20.48% (34/166) down-
regulation and 63.86% (106/166) no change in expression
of β2-M transcripts was observed in the breast cancer
specimens. In addition, no significant correlations were
found between β2-M transcript expression level and age,
clinical stage or lymph node metastasis; 18.67% (31/166)
up-regulation, 28.92% (48/166) down-regulation and
52.41% (87/166) no change in expression of Bcl-2 tran-
scripts were observed in the breast cancer specimens, and
no significant correlations were found between Bcl-2 tran-
script expression level and age, clinical stage or lymph
node metastasis.
Expression of β2-M transcripts in different breast cancer
molecular subtypes
The expression levels of the β2-M transcripts in different






0.67 8 37 12 0.483
11 19 10
0.739 4 13 5 0.907
24 61 36
3 11 7
0.316 5 17 12 0.981
7 27 19




0.731 19 51 28 0.840
10 22 15
0.426 14 40 28 0.336
15 33 15
Li et al. BMC Cancer 2014, 14:750 Page 5 of 9
http://www.biomedcentral.com/1471-2407/14/750The expression levels of the β2-M transcripts, includ-
ing up-regulation, down-regulation and no change,
demonstrated that there was no significant difference
in the four breast cancer molecular subtypes (P = 0.928).
No significant difference was observed in β2-M tran-
script expression levels between the ER+ and ER− breast
cancer groups (P = 0.731) and the HER-2+ and HER-2−
breast cancer groups (P = 0.426). There was no signifi-
cant difference in the expression levels of Bcl-2 tran-
scripts in the four breast cancer molecular subtypes,
including up-regulation, down-regulation and no change
(P = 0.282). In addition, no significant difference was
observed in Bcl-2 transcript expression between the
ER+ and ER− breast cancer groups (P = 0.840) and
HER-2+ and HER-2− breast cancer groups (P = 0.336)
(Table 4).Association of β2-M transcript expression with Bcl-2
transcript expression
The association of β2-M transcript expression with Bcl-2
transcript expression is shown in Table 5. The β2-M tran-
script expression levels have a positive correlation with
Bcl-2 transcript expression levels (P = 0.011).Expression of β2-M protein in the breast cancer tissues
The paraffin-embedded sections from the 164 patients’
specimens with breast cancer and the 123 patients with be-
nign breast tumors were immunohistochemically stained
using β2-M, ER, PR, HER-2, p53 and Ki67 antibodies
(Figure 1). The results demonstrate that 67.68% (111/164)
of sections from breast cancer patients were positively
stained by the β2-M antibody, which is significantly higher
than the 34.14% (42/123) positive staining from patients
with benign breast tumors (P < 0.01). No significant corre-
lations were found between β2-M protein expression and
age, clinical stage or lymph node metastasis. In addition,
37.03% p53 and 88.40% Ki67 positive staining were found
in the breast cancer patient sections, and no significant
correlations were found between p53 protein expression
and age, clinical stage or lymph node metastasis. The ex-
pression of the Ki67 protein had a significant correlation
with lymph node metastasis (P < 0.01), but no significant






No difference 31 68
Down-regulation 8 12
Total no. 59 94Expression of β2-M protein in different breast cancer
molecular subtypes
The β2-M protein expression levels in different breast
cancer molecular subtypes are shown in Table 6. The ex-
pression levels of β2-M protein demonstrate significant
differences in the four breast cancer molecular subtypes
(P = 0.034); the rate of positive staining was 56.25%
(Luminal A), 53.33% (Luminal B), 84.61% (Overexpression
of HER-2) and 73.68% (Basal-like). Significant differences
were also observed in the β2-M protein expression levels
between the ER+ and ER− breast cancer groups (P < 0.01);
58.09% (ER+) and 81.39% (ER-) positive staining were ob-
served in the breast cancer specimen sections. There was
no significant difference in the β2-M protein expression
levels between HER-2+ and HER-2− breast cancer groups
(P = 0.180). Both p53 and Ki67 proteins demonstrated
significant differences in expression between the four
molecular subtypes (P < 0.01), between the ER+ and ER−
groups (P < 0.01), and between HER-2+ and HER-2− breast
cancer groups (P < 0.01).
Association of β2-M protein expression with ER, p53 and
Ki67 protein expression
The association of β2-M protein expression level with ER,
p53 and Ki67 protein expression levels is shown in Table 7.
The level of β2-M protein expression has a negative cor-
relation with ER protein expression (P < 0.01), a positive
correlation with p53 protein expression (P < 0.01) and no
correlation with Ki67 protein expression (P = 0.6).
Silencing of β2-M gene by pre-designed siRNAs
Silencing effects of the pre-designed β2-M siRNAs were
examined in MCF-7 and MDA-MB-231 cells, and a
scrambled siRNA was used as the negative control. All
three siRNAs showed a significant silencing effect (P <
0.01) and knocked down 80 to 98% of the β2-M mRNA
in comparison with the scrambled siRNA (Figure 2).
Among the β2-M siRNAs tested, only the siR-3 siRNA
showed a significant effect on downstream genes and
therefore this siRNA was selected for silencing of the
β2-M gene. The mRNA transcript and protein expres-
sion levels of β2-M, ER, PR, HER-2 and Bcl-2 were de-
tected by real-time PCR and western blotting after β2-M








Figure 1 β2-M IHC staining in breast cancer tissue. A) Strong cytomembrane staining; B) Strong cytoplasm staining; C) Moderate cytoplasm
staining; D) Weak cytoplasm staining; E) Negative staining. The tissue sections were examined under a microscope at a magnification of 200×.
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pression, but did not inhibit the levels of ER, PR, and
HER-2 mRNA expression in MCF-7 cells, which is con-
sistent with the silencing effect at the protein level. The
Bcl-2 and HER-2 mRNAs were significantly up-regulated
by siR-3 silencing in MDA-MB-231 cells, which is alsoTable 6 Expression of β2-M protein in different breast cancer
Variable
β2-M
Positive staining P-value Po
(%)
Breast cancer 67.68 (111/164) <0.01
Benign breast tumor 34.14 (42/123)
Age (years)
<59 65.87 (83/126) 0.617
>60 70.27 (26/ 37)
Stage
I + II 61.81 (34/55) 0.515
III + IV 68.96 (20/29)
Lymph node metastasis
Present 67.79 (40/59) 0.956
Absent 68.25 (43/63)
Molecular subtype
Luminal A 56.25 (36/64) 0.034
Luminal B 53.33 (16/30)
Overexpression of HER-2 84.61 (22/26)
Basal-like 73.68 (14/19)
ER+ 58.06 (54/93) <0.01
ER− 81.39 (35/43)
HER-2+ 72.41 (42/58) 0.180
HER-2− 61.62 (53/86)consistent with the silencing effect at the protein level
(Figure 2).
Discussion
Overexpression of β2-M has been observed in patients
with breast cancer [6,9], and studies have shown thatmolecular types
p53 Ki67
sitive staining P-value Positive staining P-value
(%) (%)
38.83 (40/103) 0.506 90.56 (96/106) 0.130
32.15 (10/31) 80.64 (25/31)
25.53 (12/47) 0.227 82.97 (39/47) 0.136
34.78 (8/23) 95.65 (22/23)
40.00 (18/45) 0.279 97.82 (45/46) <0.01
29.62 (16/54) 79.62 (43/54)
25.00 (16/64) <0.01 77.41 (48/62) <0.01
32.00 (8/25) 96.15 (25/26)
70.83 (17/24) 100.00 (26/26)
38.88 (7/18) 94.44 (17/18)
27.05 (23/85) <0.01 82.75 (72/87) <0.01
56.09 (23/41) 100.00 (43/43)
50.98 (26/51) <0.01 98.11 (52/53) <0.01
28.04 (23/82) 83.13 (69/83)
Table 7 Association of β2-M protein expression with ER,




Positive (+) Negative (−) Total no.
Case no. 85 56 141 <0.01
ER+ 46 47 93
ER− 39 9 48
Case no. 84 52 136 <0.01
p53+ 36 13 49
p53− 48 39 87
Case no. 81 52 133 0.60
Ki 67+ 73 46 119
Ki 67− 8 6 14
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study, our results show that: (1) the expression of β2-M
transcripts only demonstrate a 15.66% up-regulation in
the breast cancer specimens, no significant difference in
the four breast cancer molecular subtypes, and no signifi-
cant correlations with age, clinical stage or lymph node
metastasis. β2-M transcript expression has a positive cor-
relation with Bcl-2 transcript expression. (2) Overexpres-
sion of the β2-M protein was significantly higher in breast
cancer tissues compared to that in benign breast tumors,
and has no significant correlation with age, clinical stageFigure 2 Silencing of the β2-M gene by siRNAs in breast cancer cells.
did not inhibit the ER, PR, and HER-2 mRNA expression in MCF-7 cells (ER+,
and HER-2 mRNA expression in MDA-MB-231 cells (ER−, PR− and HER-2−); C
β2-M siRNAs; D) ER, HER-2, PR and Bcl-2 protein levels in MDA-MB-231 cellor lymph node metastasis in breast cancer. Expression
levels of the β2-M protein are significantly different in the
four breast cancer molecular subtypes, significant differ-
ences were demonstrated between the ER+ and ER− breast
cancer groups, but not between the HER-2+ and HER-2−
breast cancer groups. (3) β2-M protein expression has a
negative correlation with ER protein expression, a positive
correlation with p53 protein expression and no correlation
with Ki67 protein expression. (4) β2-M siRNAs have dif-
ferent silencing effects in the different breast cancer mo-
lecular subtypes; it significantly inhibited Bcl-2 mRNA
expression and did not inhibit the ER, PR and HER-2
mRNA expression in MCF-7 cells (ER+, PR+ and HER-2−);
however, there was significant up-regulation in the Bcl-2
and HER-2 mRNA expression levels in MDA-MB-231
cells (ER−, PR− and HER-2−), which is also consistent with
the silencing effect at the protein level.
In conclusion, the aforementioned results demonstrate
the following. First, the expression levels of the β2-M
transcript show no significant difference between differ-
ent breast cancer molecular subtypes, and no significant
association with age, clinical stage or lymph node metas-
tasis. Second, the expression level of the β2-M protein
was significantly up-regulated by upstream genes or fac-
tors in breast cancer; its expression has different regula-
tion pathways in the different breast cancer molecular
subtypes, and has a negative correlation with ER proteinA) β2-M siRNAs significantly inhibited the Bcl-2 mRNA expression, but
PR+ and HER-2−); B) β2-M siRNAs significantly up-regulated the Bcl-2
) ER, HER-2, PR and Bcl-2 protein levels in MCF-7 cells, with or without
s, with or without β2-M siRNAs.
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may be regulated by other signaling pathways beside the
ER signaling pathway; the mechanism of this regulation
needs to be further defined. Third, β2-M transcript ex-
pression has a positive correlation with Bcl-2 transcript
expression. Consequently, the overexpression of β2-M
transcripts may cause up-regulation of the Bcl-2 tran-
scripts in breast cancer, and restrain apoptosis in breast
cancer cells. Bcl-2 is a target protein of the ER genome
singling pathway in breast cancer cells (MCF-7), and mod-
ulates apoptosis in breast cancer cells [16]. ERα is a key
molecule of ER singling pathway [17,18], and estrogen can
markedly promote the proliferation of breast cancer cells
with ERα overexpression [19]. Therefore, β2-M may pro-
mote proliferation and restrain apoptosis in breast cancer
cells through the ER genome singling pathway in breast
cancer with ER overexpression. Fourth, β2-M siRNAs sig-
nificantly inhibited Bcl-2 mRNA expression, but did not
inhibit ER, PR and HER-2 mRNA expression in breast
cancer cells with ER+, PR+ and HER-2− status. In contrast,
there was significant up-regulation in Bcl-2 and HER-2
mRNA expression levels in breast cancer cells with ER−,
PR− and HER-2− status. The different breast cancer mo-
lecular subtypes are caused by different pathologies [20],
are regulated by different singling pathways, and β2-M
may have different functions in the different breast cancer
molecular subtypes. Other studies have shown that β2-M
is a signaling and growth-promoting factor for human
renal cell carcinoma and prostate cancer bone metastasis.
Interrupting the β2-M signaling pathway may induce
apoptosis in tumor cells and β2-M may stimulate growth
and improve osteocalcin (OC) and bone sialoprotein (BSP)
gene expression in human prostate cancer cells via activat-
ing cyclic AMP (cAMP)-dependent PAK signaling pathway
[10,21]. Human β2-M monoclonal antibodies may have
the effect of inducing apoptosis in vitro, and have thera-
peutic effects in mouse models of myeloma and other
hematological tumor cells. The monoclonal antibodies
may induce apoptosis and accomplish therapeutic
functions by activating the c-Jun N-terminal kinase
(JNK) and the caspase-9-dependent cascade, inhibiting
PI3K (Phosphatidylinositol-3 kinase)/Akt and ERK (extra-
cellular signal-regulated kinase) [13]. β2-M may accelerate
human renal cell carcinoma cell growth via activation of
PI3K/Akt and ERK, and induce phosphorylation of the
Bcl-xL/Bcl-2-associated death promoter (Bad). The β2-M
antibody may induce the human renal cell carcinoma cells
apoptosis by inhibiting the phosphorylation of Akt and
ERK, and activating JNK, resulting in the phosphorylation
of Bcl-2 and decreased phosphorylation of Bad, leading to
apoptosis [22]. Thereby, we deduced that β2-M may resist
apoptosis by activating PI3K/Akt and ERK. Moreover, the
β2-M siRNAs inhibited Bcl-2 mRNA expression by inhi-
biting the phosphorylation of Akt and ERK in breastcancer cells with ER overexpression. HER-2 may increase
the antiapoptotic proteins survivin and Bcl-2 via activating
the ERK and PI3K signaling pathways [23]. Accordingly,
β2-M may promote apoptosis by inhibiting HER-2 expres-
sion, resulting in inhibition of PI3K/Akt and ERK signal-
ing pathways. In addition, β2-M siRNAs may up-regulate
the Bcl-2 mRNA expression via increasing HER-2 expres-
sion in breast cancer cells with ER−, PR− and HER-2− status.
However, the regulation of the β2-M signaling pathways
in the different breast cancer molecular subtypes need
further study.
Briefly, the results of this study indicate that expression
of β2-M is significant differences in four breast cancer
molecular subtypes, which may lead to different functions
of apoptosis regulation in breast cancer. These results will
also be useful to understanding β2-M signaling pathways
regulation, and help to identify new targets for the treat-
ment of breast cancer patients.
Conclusions
The expression of β2-M is significantly different in four
breast cancer molecular subtypes, and the β2-M siRNAs
have different silencing effects in the different breast
cancer molecular subtypes. β2-M may be involved in
apoptosis regulation of breast cancer, and understanding
the regulation of the β2-M signaling pathways will help
to identify new targets for the treatment of patients with
breast cancer.
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